Meet Genomadix™
Genomadix has developed the Cube, the world’s first real-time PCR point of need platform for precision medicine testing and other applications.
- Genomadix produces molecular tests for precision medicine genotyping and environmental/water safety testing.
- Genomadix commercializes the Cube CYP2C19 Genotyping Test, the world’s fastest and easiest FDA-cleared CYP2C19 genotyping test, which can be used to support dual antiplatelet therapy decisions for stroke and cardiology patients.
- The Genomadix Cube is a point of care open platform, and is available for partnering with assay developers, clinical labs, laboratory service providers, and others.
- Genomadix’s technology for the cube includes over 3 million hours of research and development, 11 patents and 23 peer-reviewed scientific publications
Management
Genomadix leadership team is comprised of visionary founders and seasoned professionals with decades of experience across diverse fields such as, life sciences, in vitro diagnostics, and high-tech. Together, they’ve achieved successful exits, launched innovative products, and spearheaded effective commercialization. Their combined expertise in business development, strategic planning, and international markets positions Genomadix for tremendous growth
Jeremy Bridge-Cook
Chief Scientific Officer (CSO) and Vice President, Research & Development (R&D)
Careers
Looking to join our growing team? Learn more about what it’s like to work at Genomadix and our current openings.